Kenna Mills Shaw, Executive Director, Institute for Personalized Cancer Therapy at MD Anderson Cancer Center, shared a post on LinkedIn about a paper by Funda Meric-Bernstam et al in Nature Reviews Clinical Oncology:
“Congratulations to Amber Johnson on bringing this labor of love from concept to community impact.
While targeted sequencing for mutations has long been necessary, it has never been sufficient.
This work challenges the precision oncology community to move beyond targeted DNA panels, an evolution many of us have advocated for, but that far fewer have successfully implemented in practice.”
Title: The actionable transcriptome: a framework for incorporating RNA sequencing into precision oncology.
Authors: Amber Johnson, Yifei Shen, Xiaofeng Zheng, Fei Su, Jia Zeng, Burak Uzunparmak, Eun-Kyoung Breuer, Vijaykumar Holla, Michael Kahle, Sun-Hee Kim, Thuy Vu, Kenna R. Mills Shaw, Ecaterina Ileana Dumbrava, Timothy A. Yap, Jordi Rodon, Mark Routbort, Keyur Patel, Shashikant Kulkarni, Donna Hansel, Julian Bryan, Anil Korkut, Ken Chen and Funda Meric-Bernstam.
You can read the full article in Nature Reviews Clinical Oncology.
More posts about Precision Oncology.